Australia's Neurotech International rises on positive results from autism therapy trial

Neurotech International

10/07/2024 05:25

** Shares of Neurotech International  NTI.AX  rise as much
as 5.4% to A$0.078, their highest level since May 22
    ** Biopharmaceutical developer says positive results
achieved from Phase II/III clinical trials of autism patients
that have received 12 weeks of NTI164 therapy
    ** NTI164 is a therapeutic drug product for a range of
neurological disorders in children where neuroinflammation is
involved
    ** Stock eyes fifth straight week of gains 
    ** About 1.9 mln shares change hands, compared with the
30-day average volume of 1.1 mln
    ** Stock has risen 7.3% this year, as of last close

 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.Kumar@thomsonreuters.com;))